Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
April 18, 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
November 13, 2023 06:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.
Knee Osteoarthritis Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies To Look Out - Techfields, Centrexion, Biosplice, Ampio, Paradigm, Grünenthal, Naturecell, MiMedx, TissueTech, Organogenesis
August 08, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Knee Osteoarthritis Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies To Look Out - Techfields, Centrexion, Biosplice,...
Global CBD Patches Market To Surge Ahead At A CAGR Of 18.7% To End Up At A Market Size Of US$ 691.9 Million By 2033
November 30, 2022 09:30 ET
|
FACT.MR
Rockville, Nov. 30, 2022 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global CBD patches market is set to reach US$ 124.6 million in 2023...
Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight
October 31, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight The prevalence of Knee...
Global Viscosupplementation Market Predicted to Generate $5,866.2 Million and Grow at 10.6% CAGR by 2027 Post Covid-19 Catastrophe | Report by Research Dive
October 26, 2022 09:01 ET
|
Research Dive
New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global viscosupplementation market is predicted to generate a revenue of $5,866.2 million and...
Global Viscosupplementation Market to Surpass US$ 5,926.6 Million by 2030, Says Coherent Market Insights (CMI)
October 12, 2022 09:40 ET
|
CMI
Seattle, Oct. 12, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global viscosupplementation market is estimated to be valued at US$ 3,146.7 million in 2022 and is expected to...
Viscosupplementation Market Registering CAGR of 4.8% to Reach a Valuation of US$ 2.89 Bn by 2030
April 27, 2022 09:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Worldwide viscosupplementation equipment sales are set to be valued at US$ 1.98 Bn in 2022. Detailed industry analysis reveals that the global...
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
September 15, 2021 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase...
Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
July 22, 2021 10:10 ET
|
Biosplice Therapeutics, Inc.
Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice...